



**PPD Business Highlights
August 2020**

**HELPING DELIVER LIFE
CHANGING THERAPIES**



2020.08.12

Making Drug Development News



PPD Signs New Service Agreement with Pfizer

- Builds on the companies' existing relationship, in which PPD provides wide-ranging expertise in global clinical development and laboratory services to support Pfizer's drug development initiatives across multiple therapeutic areas



PPD Expands Laboratory Test Portfolio for COVID-19 Therapy and Vaccine Development Programs

- Adds five new molecular, serology and functional assays designed expressly for COVID-19 vaccine and therapy development programs



PPD Extends Digital Clinical Trial Capabilities to Support Biopharma Companies During COVID-19 Pandemic

- PPD collaborating with customers, regulatory authorities and business partners to deploy innovative digital and virtual solutions



Accelerated Enrollment Solutions Launches Patient-Transfer Program to Support Clinical Trial Continuity

- Initiative transfers clinical trial patients to AES' dedicated research sites from other research facilities impacted by the coronavirus crisis

HELPING DELIVER LIFE-CHANGING THERAPIES

2

PPD

PPD Signs New Service Agreement with Pfizer

PPD has signed a new three-year agreement with Pfizer Inc. to provide drug development services to advance Pfizer's portfolio. Under the terms of the agreement, Pfizer has the right to extend the term for additional two-year periods. The agreement builds on the companies' existing relationship, in which PPD provides wide-ranging expertise in global clinical development and laboratory services to support Pfizer's drug development initiatives across multiple therapeutic areas. Financial details of the agreement were not disclosed.

PPD Expands Laboratory Test Portfolio for COVID-19 Therapy and Vaccine Development Programs

PPD has expanded its laboratory test portfolio by adding five new molecular, serology and functional assays designed expressly for COVID-19 vaccine and therapy development programs. These assays have been developed by PPD® Laboratories' bioanalytical, biomarker and vaccines sciences labs to run on multiple assay platforms and are compatible with high-throughput liquid handling so they can support large numbers of specimens, attributes that will be critical to the success of COVID-19 trials.

PPD Extends Digital Clinical Trial Capabilities to Support Biopharma Companies during COVID-19 Pandemic

PPD has extended its digital clinical trial solutions to support biopharma companies' research continuity initiatives and to help ensure patient safety as part of its integrated response to the COVID-19 pandemic. PPD's extensive, flexible suite of digital trial solutions – from electronic patient consent to telehealth to hybrid and fully decentralized/virtual trials – enables biopharmaceutical customers to advance their current and planned clinical research programs. As part of the company's long-term digital strategy, PPD is collaborating with customers, regulatory authorities and business partners to deploy innovative digital and virtual solutions.

Accelerated Enrollment Solutions Launches Patient-Transfer Program to Support Clinical Trial Continuity

Accelerated Enrollment Solutions (AES), a business of PPD, has launched a new program to help biopharmaceutical companies maintain business continuity during the global COVID-19 pandemic by transferring clinical trial patients to AES' dedicated research sites from other research facilities impacted by the coronavirus crisis. As academic and hospital-based sites turn their attention to the front-line care of COVID-19 patients, and as independent sites experience diminished operating capacity related to COVID-19 concerns, biopharmaceutical companies face the prospect of delaying or canceling clinical trials. AES' patient-transfer program is designed to address this issue through its global site organization, which includes dedicated research sites committed exclusively to clinical research.

Recognized for Excellence, Industry Leadership



As an industry-leading CRO

- Best CRO at World ADC Awards
- Best trial network at Vaccine Industry Excellence Awards
- CRO Leadership Awards (*Life Science Leader*)



As a great place to work

- Training Top 125 (employee development)
- *Forbes* 2019 Best Large Employers
- Top-Five Growth Business and Desirable Employer (Randstad Japan)
- *PharmaTimes* Clinical Researchers of the Year



As an innovator

- CIO 100 Awards honoree
- SiteCoach Named One of 2019's Most Innovative Services by PM360
- Medidata Patient First Award for decreasing patient burden in clinical trials through technology
- CSO50 Award winner for information security initiatives

HELPING DELIVER LIFE-CHANGING THERAPIES

3

PPD®

World ADC Awards

PPD named Best CRO Provider for the second time in the last three years at the World ADC Awards. This recognition affirms the excellence and dedication of PPD® Laboratories professionals in helping advance clients' antibody-drug conjugate (ADC) research to develop new anticancer therapies.

Vaccine Industry Excellence Awards

PPD named the best clinical trial network at the Vaccine Industry Excellence Awards at the World Vaccine Congress. The ViE awards celebrate the outstanding achievements of leaders who continually set standards of excellence and advocacy in the vaccine industry.

CRO Leadership Awards

PPD recognized for excellence in clinical research for ninth consecutive year by pharmaceutical and biotech executives surveyed for *Life Science Leader* magazine's CRO Leadership Awards. The recognition is based on responses from industry leaders responsible for making or influencing decisions to collaborate with CROs on clinical development programs.

Training Top 125

PPD named to *Training* magazine's 2020 Training Top 125 list recognizing excellence in employee learning and development. This marks the ninth consecutive year PPD has been named to the magazine's list of top businesses.

Forbes 2019 Best Large Employers

PPD named to *Forbes* magazine's 2019 list of America's Best Large Employers, marking the second consecutive year the company was selected.

Top-Five Growth Business and Desirable Employer (Randstad Japan)

PPD-SNBL, the joint venture of PPD, and Shin Nippon Biomedical Laboratories Ltd., one of the largest clinical development service providers in Japan, has been named a top-five growth business and desirable employer by Randstad Japan. Randstad commended PPD-SNBL for its success with staff growth and retention.

PharmaTimes Clinical Researchers of the Year

PPD was recognized for its clinical research expertise at the *PharmaTimes* Clinical Researcher of the Year competitions. In the international awards, a PPD clinical research associate (CRA) earned gold in the "Aspiring Clinical Research Associate" category. In the Americas-based competition, two PPD CRAs won gold in the "Experienced Clinical Research Associate" and "New Clinical Research Associate" categories.

CIO 100 Awards honoree

PPD was named by IDG's CIO as a 2020 CIO 100 Awards honoree for deploying a data-visualization platform enabling PPD to more quickly visualize targeted patient populations and investigator sites conducting clinical trials for pharmaceutical and biotech customers, helping speed the development of life-changing medicines. PPD was honored for its Preclarus® site and patient visualization tool, which accesses multiple sources of data to create, in real time, an interactive global map of potentially trial-eligible patients and investigator sites for clinical research programs in a wide variety of diseases and medical conditions.

SiteCoach Named One of 2019's Most Innovative Services by PM360


PPD announced that its SiteCoach training program for new clinical trial investigators has been named one of 2019's most innovative services in the life sciences industry. The recognition from PM360 – a leading magazine for marketing decision-makers in the pharmaceutical, biotech, medical device and diagnostics industries – appears in its 8th Annual Innovations Issue, a guide to the year's most compelling advancements in the life sciences.

Medidata Patient First Award for decreasing patient burden in clinical trials through technology

PPD has been selected by Medidata®, part of Dassault Systèmes, to receive its Patient First Award. The award recognizes a company that is trailblazing ways to improve lives by demonstrating a commitment to decreasing patient burden in clinical trials through technology. The nomination was based on PPD's use of electronic clinical outcome assessments (eCOA), augmented by Medidata's platform, to collect direct patient data and provide patients an uninterrupted experience from Phase III to open-label extension studies. The unified collection approach allows for immediate access of patient data in a single system in order to stage dosing and monitor the patient's condition.

CSO50 Award

PPD honored for information security initiatives demonstrating outstanding business value and thought leadership.



Copyright ©2020 PPD, Inc. All rights reserved. This presentation, including the information contained herein and commentary associated herewith ("materials"), is provided as a service of PPD. These Materials, based on publicly available information as well as the knowledge and experience of PPD's employees, have been prepared solely for informational and educational purposes and should not be relied upon for professional advice. Any further use of these Materials requires the express written consent of PPD.

HELPING DELIVER LIFE-CHANGING THERAPIES

4

PPD[®]